Hylands assists Tri-Prime Gene to pass the deliberation of the Listing Committee of the Selected Layer of the NEEQ

Tri-Prime Gene intended to raise CNY 350 million through the public offering of shares to unspecific qualified investors and listing on the selected layer. The raised funds will be mainly used for four R&D innovation projects such as clinical research of recombinant human interferon α1b aerosol inhaler, and marketing network and information construction projects.

As the special legal adviser of the listing project on the selected layer, partners and attorneys Hongwei JIANG and Qun XIAO, as well as attorneys He GAO and Xiaojun DU of Hylands Law Firm provided professional legal services such as due diligence investigation, counseling for the public offering of shares, issuance of legal opinions and so on.